Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
EXACT Therapeutics AS ( (DE:56F) ) has provided an update.
EXACT Therapeutics AS has announced the re-election of Jonathan Allis to its board of directors, granting him a total of 632,633 options, with 569,370 options vesting quarterly. This move underscores the company’s commitment to strengthening its leadership team as it continues to innovate in the field of precision medicine, potentially impacting its market position and stakeholder interests.
More about EXACT Therapeutics AS
EXACT Therapeutics AS is a clinical-stage precision medicine company that leverages ultrasound and microbubbles for targeted drug delivery in oncology. Their Acoustic Cluster Therapy (ACT®) is designed to enhance the efficacy of various therapeutic agents, including chemotherapy and immunotherapy, and is applicable to a range of indications such as oncology and brain diseases.
Average Trading Volume: 21,282
Current Market Cap: NOK163.2M
Learn more about 56F stock on TipRanks’ Stock Analysis page.